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Abstract
Introduction: Early detection of breast cancer is key to successful treatment and patient survival. We have
previously reported the potential use of gene expression profiling of peripheral blood cells for early detection of
breast cancer. The aim of the present study was to refine these findings using a larger sample size and a
commercially available microarray platform.
Methods: Blood samples were collected from 121 females referred for diagnostic mammography following an
initial suspicious screening mammogram. Diagnostic work-up revealed that 67 of these women had breast cancer
while 54 had no malignant disease. Additionally, nine samples from six healthy female controls were included.
Gene expression analyses were conducted using high density oligonucleotide microarrays. Partial Least Squares
Regression (PLSR) was used for model building while a leave-one-out (LOO) double cross validation approach was
used to identify predictors and estimate their prediction efficiency.
Results: A set of 738 probes that discriminated breast cancer and non-breast cancer samples was identified. By
cross validation we achieved an estimated prediction accuracy of 79.5% with a sensitivity of 80.6% and a specificity
of 78.3%. The genes deregulated in blood of breast cancer patients are related to functional processes such as
defense response, translation, and various metabolic processes, such as lipid- and steroid metabolism.
Conclusions: We have identified a gene signature in whole blood that classifies breast cancer patients and healthy
women with good accuracy supporting our previous findings.
Introduction
Cancer of the breast is the most common cancer among
women worldwide with an estimated 1,300,000 new
cases and 465,000 deaths annually [1]. In Norway, the
age-adjusted incidence rate for breast cancer has more
than doubled from 36.7 per 100,000 in the period 1953
to 1957 to 75.6 per 100,000 in the period 2003 to 2007
[2]. To reduce breast cancer mortality, early detection
and appropriate treatment play a key role [3]. The five-
year survival rate for stage I breast cancer in Norway in
the period 1998 to 2002 was 95%, and 16.8% for stage
IV metastatic breast cancer [2]. This emphasizes the
importance of early detection so that treatment can be
initiated as early as possible during tumor development.
Mammographic screening, physical examination and self
examination are the main modalities for breast cancer
detection today, but only mammography screening has
been shown to reduce mortality. When a tumor is
detectable in the breast, either by palpation or mammo-
graphy, the tumor might have been present for several
years and have had the ability to spread to distant
organs. The growth rate of breast tumors varies consid-
erably between subjects [4]. Some tumors grow so
rapidly that they escape a biannual screening program
and hence show clinical symptoms before detection by
mammography. In addition, mammographic sensitivity
is significantly reduced in women with dense breast tis-
sue, often seen in pre-menopausal women or those
receiving menopausal hormone therapy [5]. Due to the
low sensitivity of mammography in women with dense
breast tissue, other imaging modalities have been intro-
duced in breast cancer screening including ultrasonogra-
phy and magnetic resonance imaging (MRI). However,
ultrasound is very operator-dependent, time-consuming,
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and is associated with many false positive results. MRI is
expensive, and the high false positive rate, limited
resources and lack of universally accepted imaging
guidelines restrict the use of MRI in a screening setting.
The need for improved methods to accurately detect
breast cancer at an early stage is highly desirable.
Previous studies have found that use of peripheral
blood cells for transcriptome analysis is valuable to
assess disease-associated [6-10] and drug-response
related gene signatures [11]. We have previously demon-
strated the potential use of gene expression profiling of
peripheral blood cells for early detection of breast can-
cer [12]. Blood samples are easily available, minimally
invasive and can be collected at low cost making them
an attractive alternative modality for diagnostic pur-
poses. The rationale for using blood as a clinical sample
is that breast cancer triggers a response in circulating
blood cells, leading to a traceable change in the whole
blood gene expression signature. In this study we aimed
to refine our previous findings [12] with a different sam-
ple set, using a larger sample size and a commercially
available microarray platform.
Materials and methods
Subject information and blood sampling for microarray
experiments
Two hundred blood samples were collected between 2002
and 2004 at two Norwegian hospitals (Ullevål University
Hospital and Haukeland University Hospital) after written
informed consent under approval from the Regional Ethi-
cal Committee of Norway (Ref. no. 416-01151). The sub-
jects included were randomly selected among women
called in for a second look after a first suspect screening
mammogram. The samples were collected prior to a clini-
cal examination that includes diagnostic mammography
and biopsy or fine needle aspiration in the case of a posi-
tive mammographic finding. Cytology revealed whether
the findings were of malignant or benign origin. For the
subjects with no abnormal mammographic findings, the
standard of truth was mammography alone. From each
woman, 2.5 ml blood was collected in PAXgene™ tubes
(PreAnalytiX, Hombrechtikon, Switzerland) and left over-
night at room temperature before storing at -80°C until
use. As a result of method development and testing of var-
ious gene expression platforms, only 121 of the 200 sam-
ples initially collected were included in this study. The
diagnostic mammograms and histopathology reports
revealed that out of these 121 women, 57 had invasive
breast cancer, 10 had ductal carcinoma in situ (DCIS) and
54 had no sign of malignant disease. Of these latter 54, 12
had benign findings including fibroadenomas, cysts and
some unspecified findings (Table 1). Regarding the breast
cancer subjects, tumor stage, grade and other relevant
clinical data were recorded (Tables 1 and 2). The
individuals in the case and control groups are balanced in
relation to age, menopausal status and previous menopau-
sal hormone therapy (Table 3). In addition to the 121 sam-
ples, five blood samples were collected from two healthy
women at multiple time points (biological replicates),
three blood samples from pregnant women, and one sam-
ple from a breast feeding healthy woman were collected,
leaving 130 samples from 127 individuals for gene expres-
sion analysis (Table 1).
Study design
To control for technical variability such as different
microarray production batches, lot variations of reagents
and kits, day to day variations and effects related to dif-
ferent laboratory operators, a strict experimental design
was followed. Samples were randomly divided into
batches of 10, containing equal numbers of samples
Table 1 Clinical characteristics of the subjects included in
the study (n = 127)
Diagnosis Number of samples
Total Breast Cancer 67
Pure DCIS 10
Histological grade I 1
Histological grade II 2
Histological grade III 7
Invasive Ductal Carcinoma (IDC) 49
Histological grade I 11
Histological grade II 17
Histological grade III 16
Histological grade Unknown 5
Invasive Lobular Carcinoma (ILC) 4
Histological grade I 2
Histological grade II 2
Histological grade III 0
Other invasive 4
Invasive Tubular Carcinoma (ITC) 2
Medullary Carcinoma 1
Other/mixed cases 1
Total Non-malignant 63*
Benign changes 12
Fibroadenoma 1
Fibroadenoma and haematoma 1
Cyst 6
Unspecified findings 4
No mammographic findings 42
Controls 9
Breast feeding 1
Pregnant 3
Menstrual cycle (2 subjects) 5
Total samples 130*
* Data from biological replicates were merged leaving 127 assays for analyses.
DCIS = ductal carcinoma in situ.
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from women with breast cancer and those with no sign
of the disease. All samples within each batch were
handled together through each experimental step by one
operator alone and the operators were blinded to cancer
status. Two control samples were included in each
batch following the same experimental procedures as
the other 10. These control samples were composed of
total RNA isolated from one healthy female. The order
of the samples within each batch was randomized. In
order to correct for any batch variations, we used the
batch adjustment method described by Tibshirani [13].
A total of 13 batches including 130 samples and 26
technical controls were thus analyzed.
RNA extraction
PAXgene™ tubes were thawed over night in batches of
12 tubes and total RNA was extracted according to the
manufacturer’s protocol. Total RNA was stored at -80°C
prior to analyses. RNA quality and quantity measures
were conducted using the 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, California, USA) and the
NanoDrop ND-1000 spectrophotometer (Thermo Scien-
tific, Wilmington, Delaware, USA) respectively.
Microarray procedure
Microarray gene expression studies were conducted
using single channel Applied Biosystems Human
Genome Survey microarrays v2.0 containing 32,878
probes representing 29,098 genes. From each sample,
500 ng total RNA was amplified and labeled according
to the NanoAmp RT-IVT Labeling Kit Protocol and
hybridized onto the array for 16 hours at 55°C. Follow-
ing hybridization, slides were manually washed and pre-
pared according to the manufacturer’s recommendation
before image capturing using the AB1700 reader. Identi-
fication and quantification of gene expression signals,
signal-to-noise ratios and flagging of failed spots were
conducted using the Applied Biosystems Expression Sys-
tem software. Raw data files were exported for further
analysis.
Data analysis
Data analysis was performed using R [14] and tools
from the Bioconductor project [15], adapted to our
needs. Data was preprocessed in the following way: data
were log2 transformed while individual measurements
with signal-to-noise <3 or flag values >8,191 were set as
missing. Probes with more than 5% missing values over
all 156 arrays were excluded. Preprocessing left 156
samples and 11,217 probes for further analyses. Data
were standardized (that is, centered and scaled) and
missing values were imputed with k-nearest neighbors
imputation [16] using k = 10. Principal components
analysis and ANOVA tests for each gene revealed that
there were large batch-effects present in the data. Simi-
lar batch effects have previously been reported for the
same type of data (Dumeaux V, et al., under revision).
Each probe was individually treated for batch effects
using a one way ANOVA procedure as described by
Tibshirani [13]. The 26 technical control samples were
then excluded. For the biological replicates (multiple
samples from one subject), signal intensities were aver-
aged for each probe. Thus, 127 arrays, one from each
individual remained for analysis. Finally, within-array
normalization was conducted by global mean subtrac-
tion. The data discussed in this publication have been
deposited in NCBI’s Gene Expression Omnibus [17] and
are accessible through GEO Series accession number
[GEO:GSE16443].
Feature selection and classifier construction
The gene expression data served as predictors for pre-
dicting a dummy-coded response vector. The response
vector was given the value -1 or 1 for each sample
depending on it being a healthy control or a breast can-
cer case, respectively. A new gene expression sample
was classified as diseased if the predicted value was lar-
ger than zero and as healthy otherwise.
Partial Least Squares Regression (PLSR) [18,19] with
double cross-validation was used to construct and test
our classifier. PLSR with leave-one-out cross-validation
Table 2 ER and PR status among the 67 breast cancers
samples
Status Number of samples
ER+/PR+ 36
ER-/PR- 7
ER+/PR- 7
ER-/PR+ 1
Unknown 16
ER = estrogen receptor; PR = progesterone receptor
Table 3 Subject demographics
Demographic information Breast Cancer
N = 67
Healthy
N = 60
Age
Mean 58 56
Min 38 37
Max 82 70
Not registered 9 10
Menopausal status
Pre-menopausal 14 15
Post Menopausal 37 29
Unknown 16 16
Menopausal hormone therapy
Yes 13 13
No 54 57
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(LOO-CV) was used in combination with Jackknife test-
ing [20,21] to select significant probes. In more detail,
LOO-CV gives the optimal number of components and
a set of regression coefficients associated to each probe
and jackknife feature selection is used to select probes
with regression coefficients different from 0 (P-value ≤
0.05). A PLSR model is rebuilt on these significant
probes and LOO-CV is again used to select the optimal
number of components. Finally, the analysis described
above is incorporated in an independent loop of LOO-
CV in order to test classifier accuracy [22].
Functional enrichment analysis and biological
interpretation
Reducing significant genes to core subsets is a useful
step towards understanding biological mechanisms
underlying the gene-set association with the phenotype
of interest: a smaller number of genes are easier to
understand and facilitate biological insight into disease
processes. Global test [23] was used to identify the core
probes most strongly explaining the difference between
cases and controls. A Global test gene plot illustrates
the influence of each individual probe on the signifi-
cance result. The number of standard deviation of influ-
ence on the global test P-value above the reference line
under the null hypothesis is termed the z-score. We
identify probes with high z-scores (>2) as the core
probes. Global test is not testing any specific null
hypothesis. It is simply a useful analytical tool to reduce
genes that have previously been found differentially
expressed, to a core set, by gradually exploring the asso-
ciation of remaining genes as a set with a phenotype.
To explore functional enrichment and possible biolo-
gical interactions among the genes identified we used
the Database for Annotation, Visualization and Inte-
grated Discovery (DAVID) [24], Human Experimental/
Functional Mapper (HEFalMp) [25] and Graphle [26].
DAVID is a functional annotation tool able to extract
biological information out of a large list of genes,
while Graphle is an interactive tool displaying relation-
ships between genes predicted by HEFalMp. HEFalMp
predicts interactions between genes based on data inte-
gration of a vast number of experimental results pub-
licly available and reduce all findings to a single
measurement of relatedness [25]. Genes predicted to
relate to each other often have a tendency to be co-
regulated or are believed to carry out similar cellular
tasks.
Results
Construction and characterization of the 738 classifier
Partial Least Squares Regression (PLSR) was used for
model building while a leave-one-out cross validation
(LOO-CV) was used to evaluate the use of PLS with
LOO-CV and Jackknife testing for feature selection. We
observed a high number of latent components necessary
in the PLS model (N = 21) to achieve a cross validated
minimum in the error rate.
By using PLSR with Jackknife testing on all samples
(N = 127), a set of 738 probes were identified as signifi-
cant for disease classification (P < 0.05) between breast
cancer patients and women not having the disease. The
738 probe list predicted cases and controls with an esti-
mated accuracy of 79.5% based on LOO-CV with a sen-
sitivity of 80.6% and specificity of 78.3%. Of the 67
breast cancer samples, 54 were predicted correctly,
while 47 of the 60 healthy samples were assigned to the
correct class (Figure 1a). When plotting the sensitivity
versus 1-specificity in a receiver operating characteristics
(ROC) curve (Figure 1b), we observe a good separation
of the two groups with an area under curve (AUC) of
0.88. Of note, a permutation test (k = 2,000) of the
response variable gave a maximum accuracy of 60.6%
and AUC of 0.68 (see Figures S1 and S2 in Additional
file 1). To assess whether the results could be further
improved by a larger sample size, random balanced sub-
sets of samples were analyzed repeating the classifier
building process. Results from the analyses indicate that
accuracy could be increased with more samples. These
results could in theory have been used to estimate a
higher achievable AUC if more samples had been avail-
able. Attempts to model the results have however pro-
ven unsuccessful, consequently no upper AUC has been
estimated (see Additional file 2). Using a Fisher exact
test, we analyzed whether any of the clinical characteris-
tics were significantly overrepresented among the sub-
jects incorrectly predicted (Figure 1a). Of the false
negatives, 11 out of 13 were samples from women hav-
ing small lesions (<2 cm) including two DCIS, being sig-
nificantly overrepresented with P = 0.04. Four out of 10
subjects with DCIS are incorrectly predicted as healthy,
although not significantly (P = 0.09) overrepresented
among the false negatives. Parameters such as tumor
grade, estrogen receptor (ER) status or menopausal sta-
tus do not seem to affect the prediction of the cases in
this study. Samples from pregnant women or from
women with benign lesions were not overrepresented
among the false positives.
Global test gene plot (see Additional file 3) illustrates
the influence of each individual probe in the 738 list on
the significance result (P = 0.001). Approximately equal
numbers of probes are up-regulated (n = 395) and
down-regulated (n = 343) in blood of breast cancer
patients, with the median z-score equal to 0.55 (sd 1.70)
and 0.84 (sd 2.72) respectively. Z-score filtering (Z >2)
left 89 core up-regulated probes and 119 core down-
regulated probes. We used the core probes for gene
interaction prediction.
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Figure 1 Prediction performance. A) Raw prediction scores (breast cancer >0> non-breast cancer). Subjects with breast cancer are indicated
by red bars and healthy subjects are indicated by green bars. Among the 67 breast cancer patients, 54 were correctly predicted, while 47 of the
60 healthy samples were assigned to the correct class. False negatives (n = 13) and false positives (n = 13) can be seen in the centre of the
figure. Bars marked with * are samples from pregnant women. B) ROC curve based on the double cross-validation results Prediction of the 127
samples based on the 738 probe list. The prediction accuracy is 79.5% and the area under curve (AUC) is 0.88 reflecting a good separation of
the two groups.
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Functional enrichment analysis
Using DAVID [24] functional enrichment of the up- and
down-regulated genes were investigated separately. Out
of the 738 probes, a significant number were not anno-
tated (n = 143) or had limited biological information
and these were removed from the list along with dupli-
cate gene symbols. Four hundred and ninety-three gene
symbols from the total list were recognized by DAVID
and included in the analysis. As background for the
functional enrichment analyses, the 11,217 probes left
after preprocessing were used. When analyzing the up-
regulated genes alone we identified biological processes
such as translation, defense response to bacterium, cel-
lular biosynthetic process and response to external sti-
mulus as enriched with false discovery rate (FDR) below
20% (Table 4), while processes involving various meta-
bolic processes were enriched among the genes that
were lower expressed in breast cancer patient compared
to healthy controls (Table 5).
Graphle/HEFalMp [25] was used to predict interac-
tions between the genes within each group. When
including hundreds of genes in such analyses, giant hair-
balls of predicted interactions are generated making the
results hard to interpret. To reduce the complexity of
the interaction maps we selected only the core genes (z-
score >2) from the global test analysis (see Additional
file 3). After removing probes without annotation,
Graphle recognized 47 of the up-regulated core genes
and 95 of the down-regulated core genes and predicted
their interactions (Figure 2 and Additional file 4).
Further, we submitted only the core genes to DAVID to
look at functional enrichment within the core genes of
each group in particular (see Additional file 5).
The interaction map for the 47 core up-regulated genes
identifies two main networks and many of the genes
within each network seem to be connected to each
other with high interaction confidence (Figure 2). One
cluster includes mainly genes coding for ribosomal
Table 4 Functional enrichment of genes expressed higher in blood of breast cancer patients compared to healthy
subjects
Biological process Count % P-value Genes Fold
enrichment
FDR
GO:0006412
Translation
20 8.55% 0.0037 RPL26L1, LOC440587, RPS29, RPL37A, RPL11, UBA52, RPS3A, EEF1G, TRSPAP1,
RPL36A, RPL24, RPL17, RPL14, RPL15, RPL4, RPL6, RPS25, ETF1, AARSD1,
RPL12,
2.0 6.6
GO:0042742 Defense
response to bacterium
5 2.14% 0.0064 DEFA3, LTF, CAMP, PPBP, S100A12, 6.5 11.3
GO:0044249 Cellular
biosynthetic process
27 11.54% 0.0112 LOC440587, RPL26L1, ATP5E, UBA52, RPL11, RPL14, RPL4, ATP6V0B, RPS25,
RPS29, RPL37A, RPS3A, ATP5L, EEF1G, TRSPAP1, RPL24, RNPEPL1, RPL36A,
RPL17, GUK1, RPL15, PRODH, MTHFS, RPL6, ETF1, AARSD1, RPL12,
1.6 18.9
GO:0009605 Response
to external stimulus
16 6.84% 0.0115 DEFA3, TIRAP, S100A12, CDKN2D, NMI, CXCR3, STAT3, RALBP1, CLU, PF4,
AIF1, PPBP, C8B, CMTM5, ANXA1, GP1BB,
2.0 19.4
FDR = false discovery rate
Table 5 Functional enrichment of genes expressed lower in blood of breast cancer patients compared to healthy
subjects
Biological process Count % P-Value Genes Fold
Enrichment
FDR
GO:0044255 Cellular
lipid metabolic process
20 7.69% 0.0008 C10orf33, MBTPS1, PMVK, OSBPL7, SULT1A2, PEMT, LASS6, CMAS, SYK, PLAA,
SULT1A4, INSIG1, IDI1, FDPS, HEXA, PECI, CYP2J2, ACAA1, SULT1A1, GRN,
2.3 1.6
GO:0008202 Steroid
metabolic process
9 3.46% 0.0022 INSIG1, IDI1, MBTPS1, FDPS, PMVK, OSBPL7, SULT1A2, SULT1A1, SULT1A4, 3.8 4.0
GO:0006629 Lipid
metabolic process
21 8.08% 0.0027 C10orf33, MBTPS1, ACAT2, PMVK, OSBPL7, SULT1A2, PEMT, LASS6, CMAS,
SYK, PLAA, SULT1A4, INSIG1, IDI1, FDPS, HEXA, PECI, CYP2J2, ACAA1,
SULT1A1, GRN,
2.1 4.9
GO:0006584
Catecholamine
metabolic process
4 1.54% 0.0057 SULT1A2, HDC, SULT1A1, SULT1A4, 10.3 10.1
GO:0018958 Phenol
metabolic process
4 1.54% 0.0057 SULT1A2, HDC, SULT1A1, SULT1A4, 10.3 10.1
FDR = false discovery rate
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Figure 2 Interaction map of the core up-regulated genes. Biological network prediction of the 47 core up-regulated genes in blood of
breast cancer patients compared to controls, using edge weight cutoff 0.648 (interaction confidence). Genes marked with red asterix are
involved in defense response to bacterium.
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proteins, playing different roles in the translation
machinery. The other cluster contains among others,
genes involved in defense response to bacterium. Ten
genes are not connected to either of the clusters using
edge filter cutoff 0.648 (interaction confidence). The 95
core down-regulated genes do not appear to be as
strongly related to each other (see Additional file 4). We
observe one main cluster with genes predicted to relate
to each other with edge filter cutoff set to 0.643. Many
genes cluster in small, more vague interaction networks.
No biological processes were enriched among the 95
genes. Edge weights for the genes with highest related-
ness are listed in Additional file 6.
Finally, we compared the 738 gene list to the 37 (29
unique) genes published in our previous study [12]. We
applied the global test to our data to see whether the 37
gene set published in the initial study were differentially
expressed between cases and controls. Twenty of the 29
unique genes were found in the filtered data of the pre-
sent study, and this set of genes was not significantly
differentially expressed between the cases and controls
(see Additional file 7). Only two genes were overlapping
between the two gene lists (RPS2 and RPL14), both cod-
ing for ribosomal proteins.
Discussion
The biological signal from breast tumors recapitulated in
whole blood does not appear to be very strong, reflected
by the high number of latent components necessary in
the PLS model. Other methods such as prediction analy-
sis for microarray data (PAM) and support vector
machines (SVM) were applied but did not improve classi-
fication accuracy (data not shown). Nonetheless, our
results indicate that gene expression in whole blood
serves as a possible diagnostic tool for early detection of
breast cancer. We have identified a gene signature that
separates breast cancer patients from healthy women
with good accuracy. These results are in agreement with
the findings in the pilot study, reporting a prediction
accuracy of 82% [12] although for a different predictor.
We use a rather liberal cut-off (P- value < 0.05) in the
classifier construction and consider the probe list in bio-
logical terms, that is, several genes with moderate
changes acting in concert within a pathway. The genes
identified seem to reflect a biological response related to
breast tumor growth. We also reduced the number of
selected probes to a set of core genes more likely to be
true positives and observe that similar biological pro-
cesses are enrichment among the core genes up-regulated
in blood of breast cancer patients.
False negatives and false positives
The size of the mammary lesion is the only clinical fea-
ture that is significantly overrepresented among the
falsely predicted samples. Lesions (including DCIS) with
size below 2 cm were found significantly overrepre-
sented among the false negatives. It is reasonable that a
lower tumor burden will give a weaker response in
blood affecting the prediction efficacy.
In our previous study all three pregnant subjects
included were predicted as having breast cancer. In this
study only one of the samples from the three pregnant
women are predicted as having breast cancer.
Since mammography is the standard of truth, we can
not exclude the possibility that some of the false posi-
tives have very early stage breast cancer or other occult
tumors not detectable by existing technology. Follow-up
data of these women are unavailable so we can not ver-
ify or falsify such a hypothesis.
Biological interpretations
It is known that growing tumors communicate with the
tissue in which they thrive, and also with the cells of the
immune system of the host. The high rate of sponta-
neous occurring tumors in immunocompromised ani-
mals [27] and humans [28] reflects the inhibitory role of
the immune system on tumor growth. The blood-tumor
dialogue involves a broad spectrum of signaling mole-
cules and such active cellular crosstalk seems to be
reflected in the molecular blood signature of breast can-
cer patients discussed below.
A cancer-related gene expression signature in whole
blood might reflect this communication. An increase or
decrease of certain blood cell populations and their
activities as a response to the tumor growth may also
contribute to the observed difference.
Four biological processes are enriched with FDR below
20% when analyzing the genes up-regulated in blood of
breast cancer patients (n = 243), including translation
(GO:0006412), defense response to bacterium
(GO:0042742), cellular biosynthetic process (GO:0044249)
and response to external stimuli (GO:0009605). Among
the genes down-regulated we identify processes involving
lipid-, steroid-, catecholamine- and phenol metabolism
(GO:0044255, 0008202, 0006629, 0006584, 0018958) as
enriched.
Translation is a ribosome-mediated process where
messenger RNAs (mRNAs) are translated into proteins.
Translation is a process taking place in all cells, and it is
difficult to draw any firm conclusions from this finding.
However, in the pilot study we observed reduced
expression of transcripts involved in protein synthesis
among the breast cancer patients [12].
A defense related response observed in breast cancer
patients is in agreement with our previous findings [12].
The five genes involved in defense response to bacter-
ium are DEFA3, LTF, CAMP, PPBP and S100A12, genes
that all are either highly expressed in neutrophil
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granulocytes or activators of such. Neutrophil granulo-
cytes are the most abundant type of leukocytes (approxi-
mately 60%), whose role is to recognize and kill
microorganisms, but also tumor cells [29]. Increased
number of neutrophils (neutrophilia) is a sign of acute
bacterial infection, but has also been reported in cancer
patients, along with reduced lymphocyte counts (lym-
phocytopenia), referred to as an elevated neutrophil-
lymphocyte ratio [30,31]. Whether such a shift in blood
cell populations is due to defense related mechanisms or
as a response to tumor derived signals is still not well
understood. It has been proposed that tumor cells can
attract neutrophils by secreting interleukin 8 (IL8) and
that the neutrophils, in a similar manner as in wounds,
enhance angiogenesis, tumor growth and progression,
and finally cell migration through the ECM [32]. In con-
trast, one of the genes secreted by neutrophils; lacto-
transferrin (LTF) has been shown to have an inhibitory
effect on tumor growth and metastasis via regulation of
natural killer (NK) cell activity, modulation of expres-
sion of G1 proteins, inhibition of angiogenesis and
enhancement of apoptosis [33,34]. Interestingly, the
gene cystatin A (CSTA), a cystein proteinase inhibitor,
which is among the 49 core up-regulated genes has
been proposed as a prognostic marker for breast cancer
[35,36]. Elevated lipocalin 2 (LCN2) levels has also been
reported in tissue- and urine samples from patients with
invasive breast cancer [37] and is proposed as a nonin-
vasive biomarker for advanced breast cancer. It is
believed that LCN2 promotes breast cancer progression
by inducing epithelial to mesenchymal transition (EMT)
and by increasing cell motility and invasiveness through
down-regulation of E-cadherin.
Enrichment of genes involved in various metabolic
processes among down-regulated genes suggests a
change in the metabolism of breast cancer patients.
Tumor growth often leads to dramatic metabolic
changes in the host [38]. Several studies have shown
altered systemic lipid metabolism in cancer patients
[39], often leading to cachexia. Although cancer
cachexia is most common in patients with terminal
malignancies, it has also been observed in patients with
a relatively small tumor burden [40]. The deregulation
of lipid metabolism between cases and controls might
reflect an early shift in the metabolism of the tumor
bearer.
The gene interaction prediction analyses conducted
using Graphle indicates that many of the core up-regu-
lated genes seem to be linked to each other (Figure 2).
When looking at the functional enrichment of the core
up-regulated genes separately (see Additional file 5),
we identify defense response to bacterium as the most
significant process. This indicates that the core up-
regulated genes carry much of the biological
information that seems relevant in a blood-tumor dia-
logue context discussed above. We also identify taxis
(GO:0042330, 0006935) as enriched among the core
up-regulated genes alone. Taxis refers to movement of
cells in response to external stimulus, possibly reflect-
ing the movement of immune cells towards the grow-
ing tumor.
Conclusions
The signature identified in this study is being further
refined to improve the diagnostic accuracy. A TaqMan
based clinical test, BCtect® [41] has been developed in
part based on the results from this study. This tool
could constitute a fast and painless supplement to exist-
ing diagnostic technology, and offer a breast cancer test
in areas where mammography screening is insufficient.
Additional file 1: Contains two figures, presenting the results from
permutation tests (k = 2,000) of the response variables. Figure S1 shows
a histogram of permuted accuracy values. The red line indicates the
result presented in this study (79.5%) and is evidently better than that
achieved by chance. Figure S2 shows a histogram of permuted AUC
values. The red line indicates the result presented in this study (0.88) and
is evidently better than that achieved by chance.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/bcr2472-S1.pdf ]
Additional file 2: A figure presenting a learning curve - AUC
improvement with increasing sample size. The figure shows the
prediction accuracy with random balanced sample subsets, using an
increasing number of samples and repeating the classifier building and
testing process. The blue line indicates the mean AUC, while the light
blue lines indicate one standard deviation from the mean. The red dot
indicates result reported in this study. Extrapolation of the results does
not indicate that the upper limit has been reached. The variance of the
AUC decreases with higher percentages, this is an expected result from
using more samples to validate the classifier.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/bcr2472-S2.pdf ]
Additional file 3: A figure showing a ranked view of the 738 probes
and their influence on the global test P-value. Probes with green bars
show higher expression in blood of controls, while probes with red bars
show higher expression in blood from women having breast cancer. The
blue line indicates the influence of each probe on the global test P-value
under the null hypothesis of no association. Black horizontal lines
indicate one standard deviation of influence on the global test p-value
above the reference line under the null hypothesis. The number of
standard deviations is termed the z-score. Probes with high z-scores are
the ones that most strongly explain the differences between cases and
controls. The 208 core probes (z >2) are highlighted to the left.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/bcr2472-S3.pdf ]
Additional file 4: A figure showing the biological network prediction of
the 95 core down-regulated genes in blood of breast cancer patients
compared to controls, using edge weight cutoff 0.643 (interaction
confidence).
Click here for file
[ http://www.biomedcentral.com/content/supplementary/bcr2472-S4.pdf ]
Additional file 5: A table listing functional enrichment of core genes
up-regulated in blood of breast cancer patients compared to healthy
subjects. No biological processes were enriched among the 95 core
genes down-regulated blood of breast cancer patients compared to
healthy subjects.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/bcr2472-S5.xls ]
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Additional file 6: A table listing the interaction confidence predicted by
HEFalMp/Graphle between the core genes in each group (z-score >2).
Click here for file
[ http://www.biomedcentral.com/content/supplementary/bcr2472-S6.xls ]
Additional file 7: A figure showing the influence of twenty of the
annotated genes (some represented by multiple probes) from the 37
gene list published in the pilot study on the global test P-value in the
present dataset. As illustrated by this plot, the enrichment of this set of
20 genes was not significant in relation to disease status in the present
study. Only two of these genes are common with the 738 candidate
gene identified; RPL14 and RPS2 (purple).
Click here for file
[ http://www.biomedcentral.com/content/supplementary/bcr2472-S7.pdf ]
Additional file 8: A recruitment overview of samples included in the
study (n = 130).
Click here for file
[ http://www.biomedcentral.com/content/supplementary/bcr2472-S8.xls ]
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